In this pathological context, increased functionality of A2AR would be expected, as has been proposed in PD (Ramlackhansingh et al., 2011; Varani et al., 2010), thus supporting the therapeutic use of A2AR antagonists in PD management (Xu et al., 2005). Here, ADORA2A is linked to Parkinson disease.